Abdullah U Althemery, Rawan Alzahrani, Nura Alajlan, Abdullah M Alrajhi
{"title":"Quality of life for patients on oncology treatments in the Kingdom of Saudi Arabia: a systematic review.","authors":"Abdullah U Althemery, Rawan Alzahrani, Nura Alajlan, Abdullah M Alrajhi","doi":"10.1080/20523211.2024.2449036","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cancer cases in the Kingdom of Saudi Arabia (KSA) have tripled in recent years. Quality of Life (QoL) measurements are crucial for healthcare professionals because they reveal important information about how patients respond to drugs and their general health. This study aimed to collect and summarise articles exploring the QoL of patients undergoing oncology treatments in KSA.</p><p><strong>Methods: </strong>This systematic review captured articles on the Quality of Life of patients undergoing oncology treatments living in the KSA from 2000-2023. A query was established by adapting (PICOS) guidelines for systematic research. A systematic review accelerator (SRA) was used to organise the search and enable multiple reviewers to conduct and validate the process.</p><p><strong>Results: </strong>Twelve articles met the inclusion criteria. Riyadh and Jeddah contributed to all publications. A total of 2,430 patients with cancer were surveyed; 1,377 patients were female (56.67%) with an average age of 51.23 years. Six articles mentioned pharmacological interventions, whereas the remaining articles did not mention which pharmacology had been utilised.</p><p><strong>Conclusion: </strong>This systematic review highlights the recent attention given to the patient's reported outcomes of cancer patients. Further research on rare cancer types is required, particularly for generic instruments.</p>","PeriodicalId":16740,"journal":{"name":"Journal of Pharmaceutical Policy and Practice","volume":"18 1","pages":"2449036"},"PeriodicalIF":3.3000,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11731331/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Policy and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20523211.2024.2449036","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Cancer cases in the Kingdom of Saudi Arabia (KSA) have tripled in recent years. Quality of Life (QoL) measurements are crucial for healthcare professionals because they reveal important information about how patients respond to drugs and their general health. This study aimed to collect and summarise articles exploring the QoL of patients undergoing oncology treatments in KSA.
Methods: This systematic review captured articles on the Quality of Life of patients undergoing oncology treatments living in the KSA from 2000-2023. A query was established by adapting (PICOS) guidelines for systematic research. A systematic review accelerator (SRA) was used to organise the search and enable multiple reviewers to conduct and validate the process.
Results: Twelve articles met the inclusion criteria. Riyadh and Jeddah contributed to all publications. A total of 2,430 patients with cancer were surveyed; 1,377 patients were female (56.67%) with an average age of 51.23 years. Six articles mentioned pharmacological interventions, whereas the remaining articles did not mention which pharmacology had been utilised.
Conclusion: This systematic review highlights the recent attention given to the patient's reported outcomes of cancer patients. Further research on rare cancer types is required, particularly for generic instruments.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
